Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07629960 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 265
- Enrollment target
NCT07629960: Recruiting Phase 1 study, sponsored by Blueprint Medicines Corporation.
NCT07629960 is a Phase 1 study that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 265 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (342% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07629960, a Phase 1 study, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 265 participants
- Enrollment target
Study Summary
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Primary Outcome
Any of the prespecified AEs that are attributable to the study treatment, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.
Interventions
- DRUG BLU-924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2031-07 |
| Phase | Phase 1 |
What NCT07629960 shows while recruiting
NCT07629960 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (342% higher).
The record links to 0 conditions, and to 1 intervention - of which BLU-924 is the first listed.
NCT07629960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07629960 about?
NCT07629960 is a clinical study titled "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations". A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
What is the current status of trial NCT07629960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 265 participants. The study started on 2026-06-30. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07629960?
The interventions under investigation include: BLU-924 (DRUG).
Who is sponsoring clinical trial NCT07629960?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07629960's enrollment target sits among peer trials
265 154th of 2000 higher than 1,844 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI